18.7% Average Loss With Semaglutide 7.2 mg at 72 Weeks
STEP UP found semaglutide 7.2 mg led to 18.7% average weight loss at 72 weeks in adults with obesity, with comparison, safety context, and study limits.
At week 72, mean body-weight change was −18.7% with semaglutide 7.2 mg, −15.6% with 2.4 mg, and −3.9% with placebo.
1,407 adults without diabetes and with BMI of at least 30; 1,005 received semaglutide 7.2 mg, 201 received 2.4 mg, and 201 received placebo; 72 weeks. Read the linked peer-reviewed source for the full methodology, findings, and limitations.
Wharton et al., Lancet Diabetes & Endocrinology 2025 · STEP UP